Tocagen Inc.'s disclosure that the independent data monitoring board for its ongoing phase III trial in recurrent high-grade glioma (HGG) recommended the study continue without modification following a planned interim analysis drew mixed reactions from analysts and sent shares of the San Diego-based company (NASDAQ:TOCA) falling 38% Wednesday.